Fosså S D, Droz J P, Pavone-Macaluso M M, Debruyne F J, Vermeylen K, Sylvester R
Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
Eur J Cancer. 1992;28A(4-5):878-80. doi: 10.1016/0959-8049(92)90139-s.
32 patients with metastatic renal cell carcinoma (MRCC) who had had no prior chemotherapy received vinblastine 0.15 mg/kg intravenously once weekly for 6 weeks, thereafter every second week, provided no major toxicity. Dose modifications were based on haematological and neurological side-effects. Only one complete response was observed among 26 evaluable patients (response rate: 4%; 95% confidence interval: 0-20%). 4 out of 29 patients developed grade 3 leukopenia. Grade 3 peripheral neurotoxicity was recorded in 2 patients. 2 patients had grade 3 alopecia. Vinblastine has no major significance on the clinical management of MRCC.
32例既往未接受过化疗的转移性肾细胞癌（MRCC）患者接受长春花碱静脉注射，剂量为0.15mg/kg，每周1次，共6周，之后每2周1次，前提是无严重毒性。剂量调整基于血液学和神经学副作用。在26例可评估患者中仅观察到1例完全缓解（缓解率：4%；95%置信区间：0-20%）。29例患者中有4例发生3级白细胞减少。2例患者记录有3级周围神经毒性。2例患者出现3级脱发。长春花碱对MRCC的临床治疗无重大意义。
